← Back

Beijing Kawin Technology Share-holding Co Ltd

Beijing Kawin Technology Share-Holding Co., Ltd. is a biopharmaceutical company that provides treatment solutions for viral and immune diseases in China and internationally. Its products include recombinant human interferon alfa-2b injection, interferon alfa-2b vaginal effervescent tablets, coblopasvir hydrochloride capsules, sofosbuvir tablets, peginterferon alfacon-2 injection, compound glycyrrhizin tablets, capsules and injections, and pirfenidone tablets for mild to moderate idiopathic pulmonary fibrosis. The company is also engaged in contract manufacturing and contract development and manufacturing, technology and biotechnology development and consulting, technology promotion and application, and wholesale of pharmaceuticals. Incorporated in 2008, it is based in Beijing, China.

Price · split & dividend adjusted
News & notes moving 688687.CG
688687.CG4

Kaiyin Technology's 2026 interim net profit was 26.7466 million yuan, down 43.55% year-on-year

Kaiyin Technology released its 2026 interim report, with net profit attributable to the parent company of 26.7466 million yuan, a decrease of 43.55% compared with the same period last year. The company's total operating revenue was 477 million yuan, down 15.82% year-on-year; net cash inflow from operating activities was 7.1608 million yuan, down 41.61% year-on-year. The latest asset-liability ratio was 32.33%, an increase of 4.10 percentage points from the same period last year; gross margin was 77.99%, a decrease of 5.90 percentage points; ROE was 1.57%, a decrease of 1.00 percentage point. Diluted earnings per share was 0.15 yuan, down 46.43% year-on-year.
Jiemian·26dRead more →